553 related articles for article (PubMed ID: 34818089)
1. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
Narsipur N; Bulla S; Yoo C; Do B; Tran K; Gu D; Zhong L; Wilson L
J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.
Zhang TT; Wang S; Wan N; Zhang L; Zhang Z; Jiang J
Clin Ther; 2018 Jul; 40(7):1122-1139. PubMed ID: 30006069
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
4. Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study.
Gordan LN; Tan CR; Vescio R; Ye JC; Schinke C; Medhekar R; Fu AZ; Lafeuille MH; Thompson-Leduc P; Khare V; Reitan J; Milkovich G; Kaila S; Davies F; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):55-63. PubMed ID: 37838502
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma.
Patel KK; Giri S; Parker TL; Bar N; Neparidze N; Huntington SF
J Clin Oncol; 2021 Apr; 39(10):1119-1128. PubMed ID: 33411586
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
7. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.
Langer P; John L; Monsef I; Scheid C; Piechotta V; Skoetz N
Cochrane Database Syst Rev; 2024 May; 5(5):CD013595. PubMed ID: 38695605
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma.
Wong XY; Chng WJ; Aziz MIA; Ng K
Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):207-215. PubMed ID: 34904498
[TBL] [Abstract][Full Text] [Related]
11. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C
Front Oncol; 2020; 10():624661. PubMed ID: 33680948
[TBL] [Abstract][Full Text] [Related]
12. Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
Facon T; San-Miguel J; Dimopoulos MA; Mateos MV; Cavo M; van Beekhuizen S; Yuan Z; Mendes J; Lam A; He J; Ammann E; Kumar S
Adv Ther; 2022 May; 39(5):1976-1992. PubMed ID: 35246820
[TBL] [Abstract][Full Text] [Related]
13. Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR.
Zeng X; Peng L; Peng Y; Tan C; Wan X
Clin Ther; 2020 Feb; 42(2):251-262.e5. PubMed ID: 31973936
[TBL] [Abstract][Full Text] [Related]
14. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Davies F; Rifkin R; Costello C; Morgan G; Usmani S; Abonour R; Palumbo A; Romanus D; Hajek R; Terpos E; Cherepanov D; Stull DM; Huang H; Leleu X; Berdeja J; Lee HC; Weisel K; Thompson M; Boccadoro M; Zonder J; Cook G; Puig N; Vela-Ojeda J; Farrelly E; Raju A; Blazer M; Chari A
Ann Hematol; 2021 Sep; 100(9):2325-2337. PubMed ID: 33970288
[TBL] [Abstract][Full Text] [Related]
15. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
16. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
Durie BGM; Hoering A; Sexton R; Abidi MH; Epstein J; Rajkumar SV; Dispenzieri A; Kahanic SP; Thakuri MC; Reu FJ; Reynolds CM; Orlowski RZ; Barlogie B
Blood Cancer J; 2020 May; 10(5):53. PubMed ID: 32393732
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma.
Durie BGM; Kumar SK; Usmani SZ; Nonyane BAS; Ammann EM; Lam A; Kobos R; Maiese EM; Facon T
Am J Hematol; 2020 Dec; 95(12):1486-1494. PubMed ID: 32804408
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Facon T; Kumar SK; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Wang J; Van Rampelbergh R; Uhlar CM; Tromp B; Delioukina M; Vermeulen J; Usmani SZ
Lancet Oncol; 2021 Nov; 22(11):1582-1596. PubMed ID: 34655533
[TBL] [Abstract][Full Text] [Related]
19. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P; Dimopoulos MA; Boccadoro M; Quach H; Ho PJ; Beksac M; Hulin C; Antonioli E; Leleu X; Mangiacavalli S; Perrot A; Cavo M; Belotti A; Broijl A; Gay F; Mina R; Nijhof IS; van de Donk NWCJ; Katodritou E; Schjesvold F; Sureda Balari A; Rosiñol L; Delforge M; Roeloffzen W; Silzle T; Vangsted A; Einsele H; Spencer A; Hajek R; Jurczyszyn A; Lonergan S; Ahmadi T; Liu Y; Wang J; Vieyra D; van Brummelen EMJ; Vanquickelberghe V; Sitthi-Amorn A; de Boer CJ; Carson R; Rodriguez-Otero P; Bladé J; Moreau P;
N Engl J Med; 2024 Jan; 390(4):301-313. PubMed ID: 38084760
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma.
Goudarzi Z; Shahtaheri RS; Najafpour Z; Hamedifar H; Ebrahimi H
Cost Eff Resour Alloc; 2024 Feb; 22(1):17. PubMed ID: 38419054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]